Thanks Saltz for this post, your example paints a picture of the BO scenario rather than just looking at it as a black/white event. I must assume the pharm. industry is aware of pro 140 and is watching its progress from different points of view. Every BP has people on the payroll whose job it is to know what is going through clinical trials. Those employees must bring up the treatments that have a large potential market and can take market from existing treatments or there jobs are pointless. How would it be possible that a treatment that is in a multi billion growing market simply disappear with know one ever at any point seeing value from some perspective? The thought that pro 140 will continue to go through p3 trials, complete trials, file BLA and be on the market with not one pharmaceutical wanting to be a part of it is insane. It does not matter from what perspective the pharm is interested, protecting their market, getting into the market or replacing their current declining pipeline. Pro 140 can only fail if there is bad results in the data, a safety concern or they run out of money. Not one of these has been a problem in many years of injecting patients of all types and there has not been a rumor that CYDY is having trouble getting money.